Equities, good to see you here, rational and truly appreciate your efforts. I was in medicine. Immense value to patients with lymphoseek, no doubt. Very excited about the clarity of 4794 as early diagnosis of Alzheimer's and the 10s of millions it effects can be enormous. Rigs is huge, as is the manocept platform. At this point, my investment interest is first getting even (around $3), then seeing how navb is positioned at that point. Would be thrilled with a buyout at $5.
wow, you really are paid per letter, aren't you -- accurate nodal involvement is CRITICAL to proper disease STAGING and subsequent treatment, which DOES affect survival ---- you are clearly not a health care provider, but paid by letter worker.
wow, you really are paid per letter, aren't you -- accurate nodal involvement is CRITICAL to proper disease STAGING and subsequent treatment, which DOES affect survival ---- go home with your moronic lies.
flog, excuse my lack of knowledge, but who bought ANDS and ONT? What was market price and buyout price? As this is moving, I think $5 is just fine with me at this point holding at around $3 --
glad the are taking steps to overcome any hurdle to use - worried about enough revenue - $150 per dose after split with cardinal?
So that is amount of short interest up to 10/31 - NAVB declined another 40% since then post cc - seems the big volume spike at 1.11 indicates covering after 10/31 - who knows - just a ride on the backs of the big boys at this point, and hoping management doesn't burn through the $30M cash before cardinal continues their stellar marketing
In Oct, NAVB met phase 3 end points for use of lymphoseek in head and neck cancers, working with FDA on sNDA which should be approved in 2014.
There is no question there is a market for lymphoseek. The question is how quickly market penetration can occur. It is the best products for identifying cancerous nodes EVER. Unless we have found a cure for cancer, I think there is a market for this drug.
Thanks for your comments - my broker spoke with Larson - unless sales are strong over the next year, he is very concerned about cash burn. Your confidence is encouraging, but a bit abstract. I hope you are right.
Are you confident with management and sales projections? Do you have contacts in hospitals to see if lymphoseek is actually being adopted? This is what we need to know --
So you seem confident in the company's ability to outrun their $20m/yr cash burn. Do you really think sales will be there?
Radiology, oncologists? Who can we call at hospitals to see if there is interest in this product and its adoption? Any informed docs. On the board?